NSRX
Nasus Pharma Ltd.
NYSE MKT: NSRX · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$2.75
+1.85% today
Updated 2026-05-01
Market cap
$37.24M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.72
Dividend yield
—
52W range
$0 – $10
Volume
0.2M
Nasus Pharma Ltd. (NSRX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Gross margin | — | — | — | — |
| R&D | $1.12M | $567000.00 | $335000.00 | $2.24M |
| SG&A | $926000.00 | $580000.00 | $743000.00 | $2.67M |
| Operating income | $-2.04M | $-1.15M | $-1.08M | $-4.90M |
| Operating margin | — | — | — | — |
| EBITDA | $-2.13M | $-956000.00 | $-1.52M | — |
| EBITDA margin | — | — | — | — |
| EBIT | — | — | — | — |
| Interest expense | $18000.00 | $49000.00 | $29000.00 | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-1.71M | $-1.05M | $-1.53M | $-5.86M |
| Net income growth (YoY) | — | +38.6% | -45.8% | -282.2% |
| Profit margin | — | — | — | — |